The prognostic value of metformin for advanced non-small cell lung cancer: a systematic review and meta-analysis | Zendy

Jianrong Zhang | Zendy; Jieyu Wu | Zendy; Qihua He | Zendy; Wenhua Liang | Zendy; Jianxing He | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The prognostic value of metformin for advanced non-small cell lung cancer: a systematic review and meta-analysis

Author(s) -

Jianrong Zhang,

Jieyu Wu,

Qihua He,

Wenhua Liang,

Jianxing He

Publication year - 2018

Publication title -

translational lung cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.474

H-Index - 41

eISSN - 2226-4477

pISSN - 2218-6751

DOI - 10.21037/tlcr.2018.03.14

Subject(s) - metformin , medicine , meta analysis , subgroup analysis , lung cancer , hazard ratio , oncology , web of science , diabetes mellitus , non small cell lung cancer (nsclc) , confidence interval , insulin , endocrinology , a549 cell

The prognostic value of Metformin for concurrent non-small cell lung cancer (NSCLC) has been controversial in previous individual studies and meta-analyses. In order to further investigate the value of this medication, we conducted a systematic review and meta-analysis for patients with advanced or inoperable NSCLC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research